Cargando…
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Within less than a decade since its inception, CRISPR-Cas9-based genome editing has been rapidly advanced to human clinical trials in multiple disease areas. Although it is highly anticipated that this revolutionary technology will bring novel therapeutic modalities to many diseases by precisely man...
Autores principales: | Behr, Matthew, Zhou, Jing, Xu, Bing, Zhang, Hongwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424283/ https://www.ncbi.nlm.nih.gov/pubmed/34522582 http://dx.doi.org/10.1016/j.apsb.2021.05.020 |
Ejemplares similares
-
CRISPR/Cas9 therapeutics: progress and prospects
por: Li, Tianxiang, et al.
Publicado: (2023) -
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021) -
CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications
por: Cheng, Hao, et al.
Publicado: (2021) -
Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies
por: Kang, Xianhui, et al.
Publicado: (2023) -
Recent Advances in CRISPR/Cas9 Delivery Strategies
por: Yip, Bon Ham
Publicado: (2020)